




aln collaboration with bluebird bio, Inc. bluebirdbio bluebirdbio



^aFiling for regulatory approval based on pivotal phase 2 data. ^bLisocabtagene maraleucel. ^cIn collaboration with Acceleron Pharma, Inc. **ACCELERON**



	Area of Research	Phase 1	Phase 2	Phase 3	Post-Approval Research
SOLID TUMORS					
Paclitaxel protein-bound particles for injectable suspension (albumin-bound) (US)/paclitaxel formulated as albumin-bound nanoparticles (EU)	Breast: Metastatic				
	Non-small cell lung: Advanced (First-line)				
	Pancreatic: Metastatic (First-line)				
	Pancreatic: Adjuvant				
	Gastric: Metastatic (Japan) ^a				
Marizomib	Glioblastoma				
Tislelizumab (BGB-A317) ^b	Non-small cell lung cancer				
CC-90011					
CC-90010 (BET inhibitor)					
CC-95251					
INFLAMMATION & IMMU	NOLOGY				
Apremilast	Psoriatic arthritis				
	Psoriasis (Mild to Moderate)				
	Psoriasis (Moderate to Severe)				
	Psoriasis (Pediatric)				
	Behçet's disease				
	Scalp psoriasis				
	Genital psoriasis				
Ozanimod	Relapsing multiple sclerosis				
	Ulcerative colitis				
	Crohn's disease				
CC-93538	Eosinophilic esophagitis				
Iberdomide (CC-220)	Systemic lupus erythematosus				
CC-90001	Idiopathic pulmonary fibrosis				
CC-90006	Psoriasis				



^aTrial conducted by licensee partner, Taiho Pharmaceuticals Co. Ltd. ^bIn collaboration with BeiGene, Ltd. 🖫 BeiGene